Hallucinations in narcolepsy with and without cataplexy: Contrasts with Parkinson's disease

Sleep Medicine

Volumn 12, Issue 5, 2011, Pages 497-504

  Leu Semenescu, Smaranda ^a,b   De Cock, Valerie Cochen ^c   Le Masson, Valerie Dauriac ^d   Debs, Rachel ^e   Lavault, Sophie ^a   Roze, Emmanuel ^a   Vidailhet, Marie ^a,b   Arnulf, Isabelle ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^c GUI DE CHAULIAC HOSPITAL   (France)

^d CENTRE HOSPITALIER SAINTE ANNE   (France)

^e CHU PURPAN   (France)

Author keywords

Hallucinations; Narcolepsy; Parasomnias; Parkinson's disease; Psychosis; Sleep paralysis

Indexed keywords

ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MAZINDOL; METHYLPHENIDATE; OREXIN A; OXYBATE SODIUM; VENLAFAXINE;

ADULT; ARTICLE; AUDITORY HALLUCINATION; CATAPLEXY; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DELUSION; FEMALE; HALLUCINATION; HUMAN; HYPOCRETIN 1 DEFICIENCY; INTERVIEW; INTROSPECTION; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NARCOLEPSY; PARASOMNIA; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RISK FACTOR; SLEEP; SOMNOLENCE; WAKEFULNESS;

ADULT; DREAMS; FEMALE; HALLUCINATIONS; HUMANS; ILLUSIONS; MALE; MIDDLE AGED; MOTOR SKILLS DISORDERS; NARCOLEPSY; PARKINSON DISEASE; QUESTIONNAIRES; REM SLEEP BEHAVIOR DISORDER; RISK FACTORS; SLEEP PARALYSIS; SLEEP STAGES; YOUNG ADULT;

EID: 79955090702     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2011.03.006     Document Type: Article

References (46)

1. Goswami M. The influence of clinical symptoms on quality of life in patients with narcolepsy. Neurology 1998, 50:S31-S36.
2. Okun M.L., Lin L., Pelin Z., et al. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep 2002, 25:27-35.
3. Dahmen N., Kasten M., Mittag K., et al. Narcoleptic and schizophrenic hallucinations. Implications for differential diagnosis and pathophysiology. Eur J Health Econ 2002, 3(Suppl 2):S94-S98.
4. Fortuyn H.A., Lappenschaar G.A., Nienhuis F.J., et al. Psychotic symptoms in narcolepsy: phenomenology and a comparison with schizophrenia. Gen Hosp Psychiatry 2009, 31:146-154.
5. Knudsen S., Gammeltoft S., Jennum P.J. Rapid eye movement sleep behaviour disorder in patients with narcolepsy is associated with hypocretin-1 deficiency. Brain 2010, 133:568-579.
6. Kryger M.H., Walid R., Manfreda J. Diagnoses received by narcolepsy patients in the year prior to diagnosis by a sleep specialist. Sleep 2002, 25:36-41.
7. Cochen V., Arnulf I., Demeret S., et al. Vivid dreams, hallucinations, psychosis and REM sleep in Guillain-Barre syndrome. Brain 2005, 128:2535-2545.
8. Fénelon G., Mahieux F., Huon R., et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000, 123:733-745.
9. Barnes J., David A. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 2001, 70:727-733.
10. Diederich N.J., Fenelon G., Stebbins G., et al. Hallucinations in Parkinson disease. Nat Rev Neurol 2009, 5:331-342.
11. Arnulf I., Bonnet A.M., Damier P., et al. Hallucinations, REM sleep and Parkinson's disease. Neurology 2000, 55:281-288.
12. Arnulf I., Konofal E., Merino-Andreu M., et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002, 58:1019-1024.
13. Gagnon J.F., Bedard M.A., Fantini M.L., et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002, 59:585-589.
14. De Cock V.C., Vidailhet M., Leu S., et al. Restoration of normal motor control in Parkinson's disease during REM sleep. Brain 2007, 130:450-456.
15. Peyron C., Faraco J., Rogers W., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6:991-997.
16. Thannickal T.C., Nienhuis R., Siegel J.M. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep 2009, 32:993-998.
17. Fronczek R., Overeem S., Lee S.Y., et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007, 130:1577-1585.
18. Thannickal T.C., Lai Y.Y., Siegel J.M. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007, 130:1586-1595.
19. Manni R., Pacchetti C., Terzaghi M., et al. Hallucinations and sleep-wake cycle in PD: a 24-hour continuous polysomnographic study. Neurology 2002, 59:1979-1981.
20. The international Classification of Sleep Disorders - Revised 2005, American Academy of Sleep Medicine, Chicago, IL. P. Hauri (Ed.).
21. Vernet C., Arnulf I. Idiopathic hypersomnia with and without long sleep time: a controlled series of 75 patients. Sleep 2009, 32:752-759.
22. Hugues A.J., Daniel S.E., Kilford L., et al. The accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181-184.
23. Folstein M.F., Folstein S.E., McHugh P.R. " Mini-mental state" A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
24. Comella C., Nardine T., Diederich N., et al. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology 1998, 51:526-529.
25. Allen R.P., Picchietti D., Hening W.A., et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4:101-119.
26. Johns M.H. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991, 14:540-545.
27. Beck A.T., Ward C.H., Mendelson M., et al. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
28. Dubois B., Slachevsky A., Litvan I., et al. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000, 55:1621-1626.
29. Fahn S., Elton R.L. Unified Parkinson's disease rating scale. Recent developments in Parkinson's disease 1987, 153-163. Members of the UPDRS Development Committee, Macmillan, Florham Park, NJ. S. Fahn, C.D. Marsden, M. Goldstein, D.B. Calne (Eds.).
30. Hobson D., Lang A., Wayne Martin W., et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease. A survey by the Canadian Movement Disorder Group. JAMA 2002, 287:455-463.
31. Moskovitz C., Moses H., Klawans H.L. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978, 135:669-675.
32. Beck A., Steer R., Brown G. Manual for the beck depression inventory 1996, The Psychological Corporation, San Francisco. 2nd ed.
33. Ohayon M.M. Prevalence of hallucinations and their pathological associations in the general population. Psychiatry Res 2000, 97:153-164.
34. Cheyne J.A., Girard T.A. Spatial characteristics of hallucinations associated with sleep paralysis. Cogn Neuropsychiatry 2004, 9:281-300.
35. Pacchetti C., Manni R., Zangaglia R., et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Mov Disord 2005, 20:1439-1448.
36. Forsaa E.B., Larsen J.P., Wentzel-Larsen T., et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 2010, 67:996-1001.
37. Goetz C.G., Ouyang B., Negron A., et al. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology 2010, 75:1773-1779.
38. Vourdas A., Shneerson J.M., Gregory C.A., et al. Narcolepsy and psychopathology: is there an association?. Sleep Med 2002, 3:353-360.
39. Vanni-Mercier G., Debilly G. A key role for the caudoventral pontine tegmentum in the simultaneous generation of eye saccades in bursts and associated ponto-geniculo-occipital waves during paradoxical sleep in the cat. Neuroscience 1998, 86:571-585.
40. Miyauchi S., Misaki M., Kan S., et al. Human brain activity time-locked to rapid eye movements during REM sleep. Exp Brain Res 2009, 192:657-667.
41. Compta Y., Santamaria J., Ratti L., et al. Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. Brain 2009, 132:3308-3317.
42. Gerashchenko D., Murillo-Rodriguez E., Lin L., et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol 2003, 184:1010-1016.
43. Alberto C.O., Trask R.B., Quinlan M.E., et al. Bidirectional dopaminergic modulation of excitatory synaptic transmission in orexin neurons. J Neurosci 2006, 26:10043-10050.
44. Bourgin P., Zeitzer J.M., Mignot E. CSF hypocretin-1 assessment in sleep and neurological disorders. Lancet Neurol 2008, 7:649-662.
45. Factor S.A., Molho E.S., Podskalny G.D., et al. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995, 65:115-138.
46. Goetz C., Vogel C., Tanner C., et al. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 1998, 51:811-814.